Business Context and Reporting Period
Ocular Therapeutix, Inc. filed this Form 8-K on January 23, 2017, to report the entry into a material definitive agreement. The company is a Delaware corporation headquartered in Bedford, MA.
Key Financial Metrics
This filing details a capital raise rather than operational performance metrics. Key figures include:
- Shares Issued: 3,571,429 shares of common stock.
- Offering Price: $6.57 per share.
- Estimated Net Proceeds: Approximately $23.2 million (after underwriting discounts, commissions, and estimated offering expenses).
- Underwriter: Cantor Fitzgerald & Co.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of an underwriting agreement to conduct an underwritten public offering. The closing of the offering was expected to take place on January 27, 2017, subject to customary closing conditions. The shares were issued pursuant to an effective shelf registration statement on Form S-3 (File No. 333-210777).
Guidance, Outlook, and Risks
The filing incorporates by reference press releases issued on January 23 and January 24, 2017, regarding the proposed and priced offering. No specific forward-looking guidance, management commentary on future operations, or detailed risk factors are contained within the body of this specific 8-K text, other than the standard closing conditions for the offering.
Investor Verification Checklist
- Verify the final closing date of the offering (expected January 27, 2017).
- Confirm the actual net proceeds received after all expenses are finalized.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific terms and conditions.
- Examine the press releases (Exhibits 99.1 and 99.2) for the intended use of proceeds.